BCAL Diagnostics has updated investors on its $10 million convertible note facility, revealing $7.6 million drawn to date with further funding contingent on upcoming shareholder approval.
- Convertible note facility of $10 million approved in November 2025
- Issued $3.1 million in notes within initial three months ending February 2026
- Additional $4.5 million drawn since then with planned drawdowns subject to approval
- Notes carry 10% annual interest, convertible into shares at a discounted price
- Remaining $2.4 million drawdown awaits shareholder approval at October 2026 AGM
Convertible Note Facility Drawdowns and Shareholder Conditions
BCAL Diagnostics Limited (ASX:BDX) has provided fresh clarity on the status of its $10 million convertible note facility, a key funding mechanism underpinning its FY2027 capital needs. Since shareholder approval at the November 2025 AGM, the company has issued $3.1 million in convertible notes within the initial three-month window ending February 2026. Subsequent drawdowns of $4.5 million have been made since, including $1 million in March, June, and August 2026, alongside a planned $1.5 million drawdown slated for the end of August.
However, BCAL has confirmed it will not access the remaining $2.4 million tranche without fresh shareholder approval, expected at the FY2026 Annual General Meeting around mid-October 2026. This procedural checkpoint is crucial, as further drawdowns beyond February 2026 without approval would erode the company’s Listing Rule 7.1 capacity, limiting its ability to issue new shares without shareholder consent.
Terms and Potential Dilution from Convertible Notes
The convertible notes carry an annual interest rate of 10%, capitalised annually, with a potential increase to 15% if conversion is delayed due to regulatory limits on shareholding thresholds. Noteholders may convert their notes into fully paid shares at a discount to the 28-day volume weighted average price (VWAP), with a minimum conversion price of approximately $0.096 and a maximum of $0.30 per share.
If all $7.6 million of notes drawn by the end of August 2026 were converted by December 31, 2026, BCAL estimates the issuance of over 50 million new shares, including capitalised interest shares. This level of potential dilution reflects a significant consideration for existing shareholders, especially as conversion decisions remain at the discretion of noteholders and subject to company consent.
Funding Purpose and Strategic Positioning
BCAL's convertible note facility funds are earmarked primarily for product commercialisation and working capital, supporting the rollout of its early cancer detection tests such as BREASTESTplus™ and the Avantect multi-cancer blood tests licensed from ClearNote Health Inc. The company’s recent funding activities, including the convertible note drawdowns and strategic investments, align with its broader plans to expand diagnostic reach and enhance commercial traction in Australia and New Zealand.
While the convertible note facility provides BCAL with a flexible funding source, the reliance on shareholder approval for further drawdowns introduces a layer of governance oversight that could influence the timing and scale of future capital inflows.
Bottom Line?
BCAL’s convertible note facility offers vital funding flexibility but hinges on upcoming shareholder approval, with significant potential share dilution looming if notes convert.
Questions in the middle?
- Will shareholders approve the remaining $2.4 million drawdown at the October AGM?
- How might potential share dilution from note conversions impact BCAL’s share price and investor sentiment?
- Could BCAL adjust its funding strategy if shareholder approval is delayed or withheld?